Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103948 · ClinicalTrials.gov registry record · Phase 2
The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
A Phase 2 study, sponsored by Eisai Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT00103948: Completed Phase 2 study, sponsored by Eisai Limited.
NCT00103948 is a Phase 2 study that has completed, run by Eisai Limited. The registered enrollment target is 165 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103948, a Phase 2 study, has completed, sponsored by Eisai Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This is an 18-week, prospective, multi-center, randomized, double-blind, placebo-controlled, (1:1) parallel-group study.
Interventions
- DRUG Aricept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103948
The ClinicalTrials.gov registry entry for NCT00103948 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aricept is the first listed.
NCT00103948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103948 about?
NCT00103948 is a clinical study titled "The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment". This is an 18-week, prospective, multi-center, randomized, double-blind, placebo-controlled, (1:1) parallel-group study.
What is the current status of trial NCT00103948?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2005-02. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00103948?
The interventions under investigation include: Aricept (DRUG).
Who is sponsoring clinical trial NCT00103948?
This trial is sponsored by Eisai Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.